Navigation Links
Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Date:6/18/2012

LAUSANNE, Switzerland and SUZHOU, China, June 18, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc. (Ascepion), a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialisation of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development. ASP-08126 is a potent orally available small molecule that binds and inhibits several tyrosine kinase oncogenes implicated in many aspects of cancer development including tumour growth, metastasis, and tumour angiogenesis. ASP-08126 is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.

"The potential of Debio 1144 to simultaneously inhibit many aspects of cancer development is making that substance extremely attractive to Debiopharm", said Rolland-Yves Mauvernay, President and founder of Debiopharm, who added "Debio 1144 has the potential of helping patients suffering from several tumour types. Due to its inhibition profile Debio 1144, is expected to lead to high anti-tumour efficacy."

"We are very pleased to collaborate with Debiopharm, a company with track records and expertise in the development of cancer medicines, to develop our innovative cancer therapeutics. The formation of this partnership will facilitate the development of ASP-08126 and benefit cancer patients ultimately", stated Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.

About Debiopharm Group

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. Debiopharm in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information on Debiopharm, please visit: http://www.debiopharm.com

About Ascepion Pharmaceuticals

Based in Suzhou, China, Ascepion Pharmaceuticals, Inc. is a leading biopharmaceutical company in China dedicated to the discovery and development of breakthrough small molecule drugs. Ascepion Pharmaceuticals possesses a fully integrated platform and proprietary technologies for the discovery and development of small molecule therapeutics targeting signal transduction pathways in a systematic and productive manner. The company has developed a pipeline of innovative small molecule drugs for the treatment of oncology and related diseases. For additional information on Ascepion Pharmaceuticals, please visit the company's website at http://www.ascepion.com .


    
    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts

    In London
    Maitland
    Brian Hudspith
    Tel.: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel.: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com

    Ascepion Pharmaceuticals, Inc. Contact
    Haiping Lin, Ph.D.
    Director, Corporate Development
    Tel: +86-512-62956001 ext 8002
    Fax: +86-512-62956001 ext 8004
    hplin@ascepion.com



'/>"/>
SOURCE The Debiopharm Group and Ascepion Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
4. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent Medical, ... Aufnahme von Patienten für eine Studie zur Sicherheit ... („WEB") speziell für die Behandlung von rupturierten intrakraniellen ... MD, Leiter der Neuroradiologie an der Universitätsklinik Bicètre ... Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
(Date:2/12/2016)... ... 2016 , ... Itopia, a leader in cloud services automation ... Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This integration ... and medium business (SMB) clients. , In recent years, BI and ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family ... eastern Texas, is launching a cooperative charity drive with the Tarrant Area Food Bank ... than 50,000 individuals and families in need, the Tarrant County Food Bank offers hope ...
Breaking Medicine News(10 mins):